

Serial No. 08/476,275

H F 6  
tive amount of immunologically active chimeric anti-CD20 antibody  
produced by <sup>a transfection comprising anti-CD20 in TCAE8,</sup> ~~transfection~~ ATCC deposit number 69119;

2) administering at a second subsequent administration period, a second therapeutically effective amount of said antibody; and

3) administering, at a third subsequent administration period, a third therapeutically effective amount of said antibody.

8  
22  
20. The method of Claim 19, wherein said first, second and third therapeutically effective amount of said antibody is between 0.001 mg/kg to about 30 mg/kg.

9  
21. The method of Claim 19, wherein said second administration period is within about seven days of said first administration period.

10  
22. The method of Claim 19, wherein said third administration period is within about fourteen days of said first administration period.--

#### REMARKS

Entry of the foregoing amendments is respectfully requested. By the present amendment, Claims 19-22 are introduced which correspond to Claims 6-9 which were inadvertently cancelled upon filing of this application.